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Highlights
 Gastrointestinal side effects with liraglutide increases with patient age 
 Patients not on metformin had more significant gastrointestinal side effects
 Renal function was not an independent predictor of gastrointestinal side 
effects
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ABSTRACT
Aim
Treatment of type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists 
may be limited by gastrointestinal side effects (GISE) in some patients. Risk factors 
for developing GISE are not known. We analysed patient characteristics that were 
associated with GISE among patients treated with the GLP-1 receptor agonist 
liraglutide.
Methods
Data was obtained from an audit database of liraglutide use based in clinical practice 
in the UK. Patients were grouped into those who did not report GISE, those who 
reported GISE but continued liraglutide and those who discontinued liraglutide due to 
GISE within 26 weeks of treatment. Baseline variables of age, diabetes duration, 
HbA1c, weight, BMI, blood pressure, lipids, gender, ethnicity, alanine 
transaminotransferase, estimated glomerular filtration rate (eGFR) and diabetes 
treatment types were tested for possible associations with GISE outcome. Significant 
variables in univariate analyses were entered into ordinal logistic regression analyses.
Results
4442 patients were suitable for analysis. 3905 (87.9%) did not report GISE, 297
(6.7%) and 240 (5.4%) had GISE and continued and discontinued treatment, 
respectively. Age, weight, eGFR, metformin status and insulin status were associated 
with GISE outcome in univariate analyses (P all <0.05). In the final regression model, 
age (adjusted OR 1.15 [95%CI 1.05,1.26], P = 0.002) and non-metformin use 
(adjusted OR 0.76 [95%CI 0.60,0.96], P = 0.020) were associated with worse GISE 
outcome.
Conclusion
Older age and non-metformin use were associated with more significant GISE leading 
to discontinuation of liraglutide treatment. The reasons for these findings are unclear 
and warrant further investigation.
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1. Introduction
Glucagon-like peptide 1 (GLP-1) secretion by intestinal L cells leads to an increase in 
insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and 
suppression of appetite. However, endogenous GLP-1 is rapidly degraded by the 
dipeptidyl peptidase-4 (DPP-4) enzyme. The use of GLP-1 receptor agonists which 
are resistant to such degradation or drugs inhibiting of the DPP-4 enzyme, forms the 
pharmacological basis of incretin-based therapies in patients with type 2 diabetes [1]. 
Liraglutide, a once-daily injected GLP-1 receptor agonist helps improve 
glycaemia and reduce weight in patients with type 2 diabetes [2]. However, a 
disadvantage of the GLP-1 receptor agonist drug class including that of liraglutide is 
the occurrence of gastrointestinal side effects (GISE). Common symptoms include 
nausea, vomiting or diarrhoea [1]. Liraglutide has been shown to have less persistent 
GISE than exenatide twice daily, the first available GLP-1 receptor agonist [3]. The 
side effects of GLP-1 receptor agonists also tend to improve with longer duration of 
treatment, possibly due to the development of tachyphylaxis [4]. However, there 
remains to be patients who discontinue drug treatment due to severe or persistent 
symptoms; between four to five percent of patients treated with liraglutide 1.2 mg 
once daily discontinued liraglutide treatment due to GISE in the Liraglutide Effect 
and Action in Diabetes (LEAD) trials [5-7]. In the United Kingdom (UK), liraglutide 
1.2 mg once daily is recommended for use by the National Institute for Health and 
Care Excellence (NICE) as a second or third line diabetes treatment after metformin 
and/or sulphonylurea in patients with body mass indices (BMI) greater than 35 kg/m2
[8].
To date, there is a lack of large-scale data on the rates of GISE among patients 
treated with GLP-1 receptor agonists in real-life clinical practice. There is also little 
data on identifying patients who may be at risk. Using information from a nationwide 
audit database of liraglutide use in clinical practice, we investigated whether there 
were identifiable risk factors for developing GISE among patients treated with 
liraglutide.
2. Methods
2.1 Subjects
Data was obtained from the Association of British Clinical Diabetologists (ABCD) 
nationwide liraglutide audit database. ABCD had invited diabetes centres in hospitals 
and primary care across UK to submit anonymised data of patients treated with 
liraglutide in routine clinical practice during the period of 2009 to 2013. 117 diabetes 
centres enrolled and submitted varying degrees of data depending on date of 
participation, the frequency of patients’ health visits and duration of liraglutide 
treatment that had taken place. Data entry and submission was performed using audit 
software provided by ABCD.
Data requested included patients’ age, gender, ethnicity, pre- and post-
liraglutide treatment information including diabetes treatments, glycated haemoglobin 
(HbA1c), body weight, BMI, blood pressure, lipid parameters, alanine 
transaminotransferase (ALT) and creatinine, whenever these data were available. 
Contributors were also asked to report on occurrence of any GISE or other possible 
treatment related adverse events, as well as the main reason for liraglutide 
discontinuation if this occurred.
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6238 patients had baseline data sent to ABCD. For this study, we excluded 
patients without at least one follow-up data submission (n=1296) and those with less 
than 13 weeks data contribution or follow-up unless these patients were noted to have 
discontinued liraglutide (n=500). Remaining 4422 patients were used for analyses.
2.2 Outcome and risk variables
Patients were classified into three GISE outcome groups: a) patients without GISE, b) 
patients reporting GISE but continued with liraglutide treatment and c) patients who 
discontinued liraglutide due to GISE before 26 weeks (the three groups were coded 0, 
1, and 2). We defined symptoms of GISE as those of nausea, diarrhoea, vomiting, 
crampy abdominal pain, constipation, belching, reflux, flatulence or similar related 
terms.
2.3 Statistical analyses
Univariate associations of all variables in the database were tested against GISE 
outcome using ANOVA, Kruskal-Wallis test and tabulated statistics depending on 
whether the variables were continuous and normally or non-normally distributed, or 
were categorical variables, respectively. Results shown for estimated glomerular 
filtration rates (eGFR) were those calculated by the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation and data on eGFR was first 
analysed as a continuous variable. Sensitivity analyses were performed using eGFR 
derived by the Cockcroft-Gault equation adjusted for body surface area using the 
DuBois formula, and the Modification of Diet in Renal Disease (MDRD) equation. 
All eGFR equations used are shown in Appendix 1 [9,10]. eGFR was also analysed as 
a categorical variable based on chronic kidney disease (CKD) groups: CKD group 1 
(eGFR >90 ml/min/1.73m2), CKD Group 2 (eGFR 60-89 ml/min/1.73m2) and CKD 
Group 3 (eGFR 30-59 ml/min/1.73m2). The associations between baseline diabetes 
treatments and GISE were also tested. In particular, the association between
metformin use and GISE was tested due to clinical trials of liraglutide generally 
showing higher rates of GISE among patients on metformin compared with patients 
on sulphonylurea [5,7,11]. The association between insulin use and GISE was tested 
due to our previous finding of more frequent reports of GISE among insulin-treated 
patients as compared with non-insulin-treated patients when started on exenatide 
twice daily [12]. Variables with statistically significant association in univariate 
analyses (P < 0.050) were entered into an ordinal logistic regression analysis, with 
liraglutide dose (1.2 mg versus 1.8 mg, and prior exenatide use treated as covariates. 
Variables in logistic regression with the highest P value were sequentially removed 
until a final model with all variables with P < 0.10 was achieved. Due to findings of 
age being a significant risk factor for GISE in the final regression model, the results of 
rates of GISE according to decades of age are also shown. Statistical analyses were 
performed using Minitab® Release 16 (Minitab Ltd, Coventry, UK).
3. Results
Baseline characteristics of the 4422 patient were, mean (±SD), age 56 ± 11 years, 
HbA1c 9.4 ± 1.7% (79 ± 19 mmol/mol), weight 110.5 ± 22.5 kg and BMI 38.8 ± 7.2
kg/m2. Median (inter-quartile range) diabetes duration was 9 [6-13] years. 41.2% of 
patients were on insulin at liraglutide initiation as opposed to the licensed prescribing 
indications for liraglutide.
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537 (12.1%) patients reported GISE of which 297 (6.7%) continued liraglutide 
treatment while 240 (5.4%) discontinued liraglutide treatment due to GISE. The total 
number of patients discontinuing liraglutide within 26 weeks of treatment, including 
those who discontinued due to GISE, was 606 (13.6%). 
Results of univariate analyses are shown in Table 1 and 2. Variables 
significantly associated with GISE were older age, lower weight, poorer renal 
function, the use of insulin and non-use of metformin (P all <0.05).
The results of ordinal logistic regression analyses are shown in Table 3. In the 
final model of 4213 patients, a rise in one standard deviation of age which 
approximated an increase of 10 years of age (adjusted OR 1.15 [95%CI 1.05,1.27], P 
= 0.002) and non-metformin use (adjusted OR for metformin versus non metformin 
use 0.76 [95%CI 0.60,0.96], P = 0.020) were associated with GISE outcome. The 
proportions of patients reporting GISE according to decades of life are shown in 
Figure 1.
Sensitivity analyses performed on eGFR derived by the Cockcroft-Gault and 
the MDRD equations showed similar findings to that when eGFR was derived by the 
CKD-EPI equation; the association of eGFR with GISE outcome in univariate 
analyses remained significant, and the association in multivariate analyses remained 
non-significant. Analysing eGFR according to CKD groups also did not alter our 
univariate or multivariate findings.
4. Discussion
Our analysis of the data from the ABCD liraglutide audit database hopes to bring 
renewed focus on the issue of drug tolerability of GLP-1 receptor agonists, rather than 
drug efficacy per se. To our knowledge, our analysis may be the first published 
attempt to characterise risk factors for developing GISE among patients treated with 
this class of treatment. There is now an expanding array of diabetes treatment options 
for type 2 diabetes beyond metformin, including sulphonylureas, thiazolidinediones, 
insulin, GLP-1 receptor agonists, DPP-4 inhibitors and more recently sodium glucose 
transporters 2 inhibitors [13]. Knowledge on potential risk factors for GISE may help 
guide clinicians in whether to select GLP-1 receptor agonists as an option for 
treatment escalation. However, the results of our study should be mainly treated as 
hypothesis-generating due to the susceptibility to biases of data in an audit, as well as 
the post-hoc decision to analyse GISE data in such a manner.
Reported rates of nausea, vomiting or diarrhoea vary between GLP-1 receptor 
agonists but were generally lower for liraglutide or exenatide once weekly as 
compared with exenatide twice daily in head-to-head studies [3,13]. In the ABCD 
audit, the rates of all combined reported GISE with liraglutide 1.2 mg were low at 
12.1%. Rates of liraglutide discontinuation due to GISE in the audit were 5.4% and 
were comparable with the rates of 4 to 5% in the LEAD trials [5-7].
Our results suggest that older age and non-metformin use are risk factors for 
GISE and drug discontinuation among patients treated with liraglutide. While eGFR 
was also significantly associated with GISE in univariate analysis, eGFR was highly 
collinear with age. Removing eGFR in the multivariate analysis resulted in the 
variable of age being significantly associated with GISE while eGFR itself did not 
achieve significance in any of our multivariate models. In increasing decades of life 
from age 30 years, there was a steady rise in reported rates of GISE (9.7% to 20.0%). 
Discordantly, there was also a high rate of reported GISE among patients age 20 to 29 
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years (15.6%) although the total number of patients were small in this group (64
patients). The reason for older age being a risk factor for more significant GISE is not 
clear. It is also possible that the higher rate of drug discontinuation in the elderly may 
signify a more precautionary approach to their management rather than them being 
more prone to developing severe GISE. Prescribing information for liraglutide 
suggests that no dose adjustment is required for patients older than 65 years, but 
highlighted the limited experience of the use of liraglutide among patients with age 
more than 75 years [14].
The findings of patients not on metformin reporting greater drug 
discontinuation due to GISE was initially a surprising finding. Clinical trials of 
liraglutide versus placebo or active comparator treatment have reported generally 
higher rates of GISE when there was background treatment with metformin [5,7] as 
compared with a trial of liraglutide added to glimepiride without background 
metformin use [10]. However, in the latter trial, glimepiride treatment was used as 
part of a forced treatment-titration rather than due to metformin intolerance. In clinical 
practice, metformin is well-recognised as the first line diabetes treatment; patients in 
the audit not on metformin were possibly those who had encountered side effects to 
metformin earlier in their treatment algorithm. However, the audit did not capture data 
that could verify this, this hence being a limitation of this study. There is a plausible 
hypothesis that patients may share intolerance to both metformin and GLP-1 receptor 
agonists. The side effect profiles for both treatments are similar. Metformin has been 
shown to increase GLP-1 levels after an oral glucose load in obese subjects with or 
without diabetes, and the rise in GLP-1 may be a possible cause of the anorectic 
effects of metformin [15].
We have previously reported more frequent discontinuation of liraglutide in 
the audit among patients with mild and moderate renal impairment, a similar finding 
in the current univariate analysis [16]. However, when adjusted for other variables 
including age, renal function became non-significantly associated with GISE 
outcomes. A pharmacokinetic study testing the 0.75 mg dose of liraglutide showed no 
increase in drug exposure in patients with renal impairment [17]. The Prescribing 
Information for liraglutide have reported that liraglutide is metabolised endogenously 
much like large proteins rather than having a specific organ as a major route of 
elimination, and with no significant elimination through the faeces or urine [14]. 
Hence our finding that poorer renal function was not an independent risk factor for 
GISE with liraglutide tr atment would be consistent with the pharmacokinetic studies 
above.
The strengths of our study include the fact that all available variables were 
tested and data was obtained from a large number of centres across UK. Weaknesses 
of the study include the potential for loss of follow-up or lack of data input among 
patients who discontinued liraglutide early due to GISE, as well as the potential for 
the audit not capturing data on other unknown determinants of GISE.
In conclusion, the results from our analyses would suggest caution in using 
liraglutide in older patients due to poorer drug tolerability. It may also be worthwhile 
investigating whether patients susceptible to GISE caused by metformin treatment are 
also at greater risk of developing GISE to GLP-1 receptor agonists.
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Table 1 - Baseline characteristics (continuous variables) and their association with the 
reporting of gastrointestinal side effects (GISE) and drug discontinuation due to GISE 
among patients treated with liraglutide
GISE status
n
No
Yes, did not 
discontinue
Yes, 
discontinued 
liraglutide
P value
Age
(years)
4213 55 ± 11 55 ± 11 59 ± 12 <0.001
Diabetes duration 
(years)
3410 9 [6-13] 9 [6-14] 10 [6-14] 0.17
HbA1c
(%; mmol/mol)
4153
9.4 ± 1.7; 
79 ± 19
9.3 ± 1.6;
78 ± 18
9.4 ± 1.7;
79 ± 19
0.85
Weight
(kg)
4262 110.7 ± 22.4 110.0 ± 24.0 106.7 ± 21.0 0.029
BMI
(kg/m2)
4173 38.9 ± 7.2 38.8 ± 7.4 38.2 ± 7.3 0.41
eGFR*
(ml/min/1.73m2)
3474 83 ± 21 84 ± 21 77 ± 23 <0.001
ALT
(U/L)
2727 28 [21-42] 30 [22-43] 29 [20-44] 0.47
TC
(mmol/L)
3486 4.3 ± 1.2 4.2 ± 1.1 4.3 ± 1.0 0.68
HDL-C
(mmol/L)
3073 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 0.80
TG
(mmol/L)
2684 2.1 [1.5-2.9] 2.0[1.4,2.9] 2.2 [1.5,3.0] 0.58
SBP
(mmHg)
3483 138 ± 18 139 ± 19 141 ± 19 0.15
DBP
(mmHg)
3483 79 ± 11 79 ± 11 78 ± 11 0.37
Variables are shown as mean ± sd or median [inter-quartile range]
BMI; body mass index, eGFR; estimated glomerular filtration rate, ALT; alanine 
transaminotransferase, TC; total cholesterol, HDL-C; high density lipoprotein 
cholesterol, TG; triglyceride, SBP; systolic blood pressure, DBP; diastolic blood 
pressure
*eGFR shown is calculated by the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation. Analyses using the Cockcroft-Gault equation 
adjusted by body surface area and Modified Diet for Renal Disease (MDRD) equation 
showed associations with significance of P = 0.001 and P = 0.009, respectively.
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Table 2 - Baseline characteristics (categorical variables) and their association with the 
reporting of gastrointestinal side effects (GISE) and drug discontinuation due to GISE 
among patients treated with liraglutide
GISE status
n
No
Yes, did not 
discontinue
Yes, 
discontinued 
liraglutide
P value
Gender
     Male
     Female
4434      2076 (88.9)
     1823 (86.9)
144 (6.2)
152 (7.2)
116 (5.0)
123 (5.9)
0.13
Ethnicity
     Caucasian
     South-Asian
     Afro-
Carribean
3673
2926 (88.1)
211 (87.9)
100 (88.5)
224 (6.8)
15 (6.3)
9 (8.0)
170 (5.1)
14 (5.8)
4 (3.5)
0.88
CKD group*
     1
     2
     3
3452
1297 (89.5)
1296 (87.8)
444 (84.4)
92 (6.3)
88 (6.0)
37 (7.0)
         61 (4.2)
         92 (6.2)
         45 (8.6)
0.004
Metformin use
     No
     Yes
4442 739 (86.5)
3166 (88.2)
49 (5.7)
248 (6.9)
         66 (7.7)
        174 (4.9)
0.003
Sulphonylurea 
use
     No
     Yes
4442 2199 (87.7)
1706 (88.2)
160 (6.4)
137 (7.1)
148 (5.9)
92 (4.8)
0.17
TZD use
     No
     Yes
4442 3141 (87.8)
764 (88.3)
239 (6.7)
58 (6.7)
197 (5.5)
43 (5.0)
0.82
Insulin use
     No
     Yes
4442 2313 (88.6)
1592 (87.0)
179 (6.9)
118 (6.4)
         119 (4.6)
         121 (6.6)
0.012
Variables are shown as n (%)
*CKD groups shown use eGFR calculated with the CKDEPI equation: CKD Group 1 
eGFR >90 ml/min/1.73m2, CKD Group 2 eGFR 60-89 ml/min/1.73m2, CKD Group 3 
eGFR 30-59 ml/min/1.73m2. Twenty two patients with eGFR < 30 ml/min/1.73m2
were excluded due to small numbers in each GISE outcome category. Analyses using 
the Cockcroft Gault equation adjusted by body surface area and Modified Diet for 
Renal Disease (MDRD) equation showed associations with significance of P < 0.001 
and P = 0.031, respectively.
TZD; thiazolidinediones
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Table 3 - Ordinal logistic regression analyses of variables associated with 
gastrointestinal side effects (GISE) or drug discontinuation due to GISE among 
patients treated with liraglutide
Model 1 Final model
Adjusted OR 
[95%CI]
P value
Adjusted OR 
[95%CI]
P value
Insulin use 1.26 [1.02,1.55] 0.035 - -
Metformin use 0.76 [0.59,0.99] 0.043 0.76 [0.60,0.96] 0.020
Age 1.11 [0.99,1.25] 0.083 1.15 [1.05,1.26] 0.002
Weight 0.96 [0.86,1.06] 0.38 - -
eGFR 0.98 [0.87,1.10] 0.68 - -
ORs represent a rise of 1-SD for continuous variable (age, weight, eGFR) and one 
category change of categorical variable (metformin use, insulin use). Results are 
sorted by P value. Model 1: all significant variables in univariate analyses; Final 
model: model after sequentially removing variables with the highest non-significant P 
value.
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Figure 1 - Rates of gastroinestinal side effects (GISE) among patients treated with 
liraglutide, results shown by decades of age. The interaction between age (decades) 
and GISE outcome was statistically significant (P < 0.001). Age 20-29 (n=64), age 
30-39 (n=236), age 40-49 (n=862), age 50-59 (n=1409), aged 60-69 (n=1261), age 
70-79 (n=339), age 80-89 (n=35). Seven patients under 20 years of age were excluded 
for clarity.
Number of patients Age (years) GISE - continued treatment
GISE - discontinued 
treatment due to 
GISE GISE - total
64 20-29 10.9 4.7 15.6
236 30-39 5.5 4.2 9.7
862 40-49 7.4 3.5 10.9
1409 50-59 6.7 4.5 11.2
1261 60-69 7.1 6.0 13.1
339 70-79 6.8 10.6 17.4
35 80-89 0 20.0 20
